Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Leonard A. Mattano, MD, Meenakshi Devidas, PhD, Alison M. Friedmann, MD MSC, Elizabeth A. Raetz, MD, Mignon Loh, MD, Patrick Buckley, MD PhD, Michael J. Borowitz, MD PhD, Andrew J. Carroll, PhD, Julie Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan-Lottick, MD MSPH, Yousif Matloub, MD, David T Marshall, MD, Linda C. Stork, MD, Brent L. Wood, MD PhD, Naomi J. Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Kelly Maloney, MD

Blood (2014) 124 (21): 793.

https://doi.org/10.1182/blood.V124.21.793.793

Published: 2014

Journal Articles

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Kelly W. Maloney, MD, Meenakshi Devidas, PhD, Leonard A. Mattano, Jr., MD, Alison M. Friedmann, MD, MSC, Patrick Buckley, MD, PhD, Michael J. Borowitz, MD, PhD, Andrew J. Carroll, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan -lottick, Mignon L. Loh, MD, Yousif Matloub, MD, David T. Marshall, MD, Linda C. Stork, MD, Elizabeth A. Raetz, MD, Brent L. Wood, MD, PhD, Naomi J. Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2013) 122 (21): 837.

https://doi.org/10.1182/blood.V122.21.837.837

Published: 2013

Journal Articles

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

Bill H Chang, MD, PhD, Stephanie G Willis, Linda C. Stork, MD, Stephen P Hunger, MD, William L. Carroll, MD, Bruce Camitta, MD, Naomi J. Winick, MD, Brian J. Druker, MD, Kirk R. Schultz, MD

Blood (2009) 114 (22): 2634.

https://doi.org/10.1182/blood.V114.22.2634.2634

Published: 2009

Journal Articles

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Faith C. Galderisi, DO, Linda C. Stork, MD, Ju Li, MD, Motomi Mori, PhD, Solange Mongoue-Tchokote, James Huang, MD

Blood (2007) 110 (11): 4232.

https://doi.org/10.1182/blood.V110.11.4232.4232

Published: 2007

Journal Articles

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Janet K. Dale, RN, Susan Price, RN, Jean Tretler, RN, Patricia Aldridge, RN, Stephanie Montague, RN MSN, Joie Davis, APRN, Fred Gill, MD, Kip R. Hartman, MD, Linda C. Stork, MD, David J. Gnarra, MD, Lakshmanan Krishnamurti, MD, Jennifer Puck, MD, Thomas Fleisher, MD, V. Koneti Rao, MD

Blood (2007) 110 (11): 1319.

https://doi.org/10.1182/blood.V110.11.1319.1319

Published: 2007

Journal Articles

Failure of Asparagine (ASN) Depletion, Not Inadequate Asparaginase (ASNase) Activity, Predicts Relapse in Standard Risk (SR) Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Vassilios I. Avramis, PhD, John S. Holcenberg, MD, Alice G. Ettinger, RN, Linda C. Stork, MD, Mei La, MS, Paul S. Gaynon, MD

Blood (2007) 110 (11): 588.

https://doi.org/10.1182/blood.V110.11.588.588

Published: 2007

Journal Articles

Early Marrow Response in CCG-1952: The Prognostic Impact of Poor Day 14 Marrow Response Is Powerful and Only Partially Reversible with Intensified Therapy.

Robert Cho, MD, Linda C. Stork, MD, Paul S. Gaynon, MD, Harland N. Sather, PhD, Mei K. La, MS, Raymond J. Hutchinson, MD

Blood (2005) 106 (11): 867.

https://doi.org/10.1182/blood.V106.11.867.867

Published: 2005

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

Journal Articles

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Suman Malempati, MD, Paul S. Gaynon, MD, Harland Sather, PhD, Mei K. La, MS, Linda C. Stork, MD

Blood (2004) 104 (11): 520.

https://doi.org/10.1182/blood.V104.11.520.520

Published: 2004

NARROW

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Failure of Asparagine (ASN) Depletion, Not Inadequate Asparaginase (ASNase) Activity, Predicts Relapse in Standard Risk (SR) Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Early Marrow Response in CCG-1952: The Prognostic Impact of Poor Day 14 Marrow Response Is Powerful and Only Partially Reversible with Intensified Therapy.

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only